Inclusion criteria:~* Patients with early signs of dementia of Alzheimer Type~* Male and female patients with
an age of at least 55 years~* Previous use of Alzheimer's Disease (AD) medications (AChEIs, memantine) is
allowed up 3 month prior to screening. Patients who are currently taking AChEIs are eligible as long as they
have been using a stable dose for at least 3 months prior to screening and no change is foreseen for the
duration of the study. This dose must be consistent with the product label in the concerned country. Patients
currently taking memantine are excluded.~* Patients must have at least 6 years of formal education and fluency
in the test language as verbally confirmed by the patient and documented by the study investigator.~* Patients
must have a reliable study partner (per investigator judgement, for instance a family member, partner etc.,
guardian or, if applicable, a legal representative)~
